Skip to main content
Erschienen in: Endocrine 1/2019

20.09.2018 | Endocrine Surgery

Surgical outcomes and predictors of glucose metabolism alterations for growth hormone-secreting pituitary adenomas: a hospital-based study of 151 cases

verfasst von: Wenqiang He, Linling Yan, Meng Wang, Qin Li, Min He, Zengyi Ma, Zhao Ye, Qilin Zhang, Yichao Zhang, Nidan Qiao, Yun Lu, Hongying Ye, Bin Lu, Xuefei Shou, Yao Zhao, Yiming Li, Shiqi Li, Zhaoyun Zhang, Ming Shen, Yongfei Wang

Erschienen in: Endocrine | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The surgical outcome on glucose metabolism in acromegaly patients is not fully understood. We aimed to investigate the impact of surgery on glucose metabolism and identify key factors that influence alterations of glucose metabolic status in acromegaly patients.

Methods

Oral glucose tolerance test was performed in 151 newly diagnosed acromegaly patients before and 3–12 months after surgery. Insulin resistance and insulin secretion was assessed. Patients were grouped as cured, discordant, and having active disease according to postoperative growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels. Receiver-operating characteristic curves were generated to determine the optimal cut-off points to predict the impact of surgery on glucose metabolism.

Results

At baseline, 32.5%, 41.7%, and 25.8% patients were categorized as having normal glucose tolerance (NGT), impaired glucose tolerance (IGT), and diabetes mellitus (DM), respectively. After surgery, improved glucose tolerance was observed in 87.3% patients with IGT and 66.7% patients with DM. Deterioration was observed in 14.3% patients with NGT. Glucose tolerance improved in patients with lower preoperative FBG, 2 h-BG, and HbA1c and higher HOMA-β and IGI/IR. The proportion of NGT was significantly increased in surgically cured patients (28.3% vs. 79.2%, P < 0.001) and those with normal GH but elevated IGF-1 levels (25.6% vs. 79.5%, P < 0.001), but not in patients with active disease (42.9% vs. 57.1%, P = 0.131). Baseline FBG < 6.35 mmol/l predicted improved glucose metabolism after surgery.

Conclusions

Glucose metabolic status improved in patients with preserved β-cell function. Preoperative FBG was an independent predictor for improved glucose tolerance status after surgery.
Literatur
1.
Zurück zum Zitat J.J. Puder, S. Nilavar, K.D. Post, P.U. Freda, Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J. Clin. Endocrinol. Metab. 90(4), 1972–1978 (2005)CrossRef J.J. Puder, S. Nilavar, K.D. Post, P.U. Freda, Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J. Clin. Endocrinol. Metab. 90(4), 1972–1978 (2005)CrossRef
2.
Zurück zum Zitat A. Colao, D. Ferone, P. Marzullo, G. Lombardi, Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 25(1), 102 (2004)CrossRef A. Colao, D. Ferone, P. Marzullo, G. Lombardi, Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 25(1), 102 (2004)CrossRef
3.
Zurück zum Zitat D.R. Clemmons, Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary 5(3), 181–183 (2002)CrossRef D.R. Clemmons, Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary 5(3), 181–183 (2002)CrossRef
4.
Zurück zum Zitat L. Katznelson, E.R. Laws Jr., S. Melmed, M.E. Molitch, M.H. Murad, A. Utz, J.A. Wass, S. Endocrine, Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933–3951 (2014)CrossRef L. Katznelson, E.R. Laws Jr., S. Melmed, M.E. Molitch, M.H. Murad, A. Utz, J.A. Wass, S. Endocrine, Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933–3951 (2014)CrossRef
5.
Zurück zum Zitat A. Goldhirsch, J.H. Glick, R.D. Gelber, H.J. Senn, A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95(7), 3141–3148 (2010)CrossRef A. Goldhirsch, J.H. Glick, R.D. Gelber, H.J. Senn, A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95(7), 3141–3148 (2010)CrossRef
6.
Zurück zum Zitat M.L. Jaffrain-Rea, G. Minniti, C. Moroni, V. Esposito, E. Ferretti, A. Santoro, T. Infusino, G. Tamburrano, G. Cantore, R. Cassone, Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly. Eur. J. Endocrinol. 148(2), 193 (2003)CrossRef M.L. Jaffrain-Rea, G. Minniti, C. Moroni, V. Esposito, E. Ferretti, A. Santoro, T. Infusino, G. Tamburrano, G. Cantore, R. Cassone, Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly. Eur. J. Endocrinol. 148(2), 193 (2003)CrossRef
7.
Zurück zum Zitat Y. Kinoshita, H. Fujii, A. Takeshita, M. Taguchi, M. Miyakawa, K. Oyama, S. Yamada, Y. Takeuchi, Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic {beta}-cell function is preserved. Eur. J. Endocrinol. 164(4), 467–473 (2011)CrossRef Y. Kinoshita, H. Fujii, A. Takeshita, M. Taguchi, M. Miyakawa, K. Oyama, S. Yamada, Y. Takeuchi, Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic {beta}-cell function is preserved. Eur. J. Endocrinol. 164(4), 467–473 (2011)CrossRef
8.
Zurück zum Zitat M. Tzanela, D.A. Vassiliadi, N. Gavalas, A. Szabo, E. Margelou, A. Valatsou, C. Vassilopoulos, Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues. Clin. Endocrinol. 75(1), 96 (2011)CrossRef M. Tzanela, D.A. Vassiliadi, N. Gavalas, A. Szabo, E. Margelou, A. Valatsou, C. Vassilopoulos, Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues. Clin. Endocrinol. 75(1), 96 (2011)CrossRef
9.
Zurück zum Zitat A.D. Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 34(Suppl 1), S62–S69 (2011)CrossRef A.D. Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 34(Suppl 1), S62–S69 (2011)CrossRef
10.
Zurück zum Zitat A.V. Dreval, I.V. Trigolosova, I.V. Misnikova, Y.A. Kovalyova, R.S. Tishenina, I.S. Barsukov, A.V. Vinogradova, B.H.R. Wolffenbuttel, Prevalence of diabetes mellitus in patients with acromegaly. Endocr. Connect. 3(2), 93–98 (2014)CrossRef A.V. Dreval, I.V. Trigolosova, I.V. Misnikova, Y.A. Kovalyova, R.S. Tishenina, I.S. Barsukov, A.V. Vinogradova, B.H.R. Wolffenbuttel, Prevalence of diabetes mellitus in patients with acromegaly. Endocr. Connect. 3(2), 93–98 (2014)CrossRef
11.
Zurück zum Zitat J. Dal, U. Feldt-Rasmussen, M. Andersen, L.O. Kristensen, P. Laurberg, L. Pedersen, O.M. Dekkers, H.T. Sorensen, J.O. Jorgensen, Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur. J. Endocrinol. 175(3), 181–190 (2016)CrossRef J. Dal, U. Feldt-Rasmussen, M. Andersen, L.O. Kristensen, P. Laurberg, L. Pedersen, O.M. Dekkers, H.T. Sorensen, J.O. Jorgensen, Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur. J. Endocrinol. 175(3), 181–190 (2016)CrossRef
12.
Zurück zum Zitat W. Yang, J. Lu, J. Weng, W. Jia, L. Ji, J. Xiao, Z. Shan, J. Liu, H. Tian, Q. Ji, Prevalence of diabetes among men and women in China. New Engl. J. Med. 362(25), 2425 (2010)CrossRef W. Yang, J. Lu, J. Weng, W. Jia, L. Ji, J. Xiao, Z. Shan, J. Liu, H. Tian, Q. Ji, Prevalence of diabetes among men and women in China. New Engl. J. Med. 362(25), 2425 (2010)CrossRef
13.
Zurück zum Zitat O. Alexopoulou, M. Bex, P. Kamenicky, A.B. Mvoula, P. Chanson, D. Maiter, Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 17(1), 81–89 (2014)CrossRef O. Alexopoulou, M. Bex, P. Kamenicky, A.B. Mvoula, P. Chanson, D. Maiter, Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 17(1), 81–89 (2014)CrossRef
14.
Zurück zum Zitat S. Fieffe, I. Morange, P. Petrossians, P. Chanson, V. Rohmer, C. Cortet, F. Borson-Chazot, T. Brue, B. Delemer, F.A. Registry, Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French acromegaly registry. Eur. J. Endocrinol. 164(6), 877 (2011)CrossRef S. Fieffe, I. Morange, P. Petrossians, P. Chanson, V. Rohmer, C. Cortet, F. Borson-Chazot, T. Brue, B. Delemer, F.A. Registry, Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French acromegaly registry. Eur. J. Endocrinol. 164(6), 877 (2011)CrossRef
15.
Zurück zum Zitat S. Kasayama, M. Otsuki, M. Takagi, H. Saito, S. Sumitani, H. Kouhara, M. Koga, Y. Saitoh, T. Ohnishi, N. Arita, Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin. Endocrinol. 52(5), 549–555 (2000)CrossRef S. Kasayama, M. Otsuki, M. Takagi, H. Saito, S. Sumitani, H. Kouhara, M. Koga, Y. Saitoh, T. Ohnishi, N. Arita, Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin. Endocrinol. 52(5), 549–555 (2000)CrossRef
16.
Zurück zum Zitat R. Helseth, S.M. Carlsen, J. Bollerslev, J. Svartberg, M. Øksnes, S. Skeie, S.L. Fougner, Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response. Endocrine 51(2), 298–307 (2016)CrossRef R. Helseth, S.M. Carlsen, J. Bollerslev, J. Svartberg, M. Øksnes, S. Skeie, S.L. Fougner, Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response. Endocrine 51(2), 298–307 (2016)CrossRef
17.
Zurück zum Zitat A. Colao, R. Attanasio, R. Pivonello, P. Cappabianca, L.M. Cavallo, G. Lasio, A. Lodrini, G. Lombardi, R. Cozzi, Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab. 91(1), 85–92 (2006)CrossRef A. Colao, R. Attanasio, R. Pivonello, P. Cappabianca, L.M. Cavallo, G. Lasio, A. Lodrini, G. Lombardi, R. Cozzi, Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab. 91(1), 85–92 (2006)CrossRef
18.
Zurück zum Zitat A. Colao, R.S. Auriemma, M. Galdiero, P. Cappabianca, L.M. Cavallo, F. Esposito, L.F. Grasso, G. Lombardi, R. Pivonello, Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J. Clin. Endocrinol. Metab. 94(2), 528–537 (2009)CrossRef A. Colao, R.S. Auriemma, M. Galdiero, P. Cappabianca, L.M. Cavallo, F. Esposito, L.F. Grasso, G. Lombardi, R. Pivonello, Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J. Clin. Endocrinol. Metab. 94(2), 528–537 (2009)CrossRef
19.
Zurück zum Zitat C.L. Ronchi, V. Varca, P. Beck-Peccoz, E. Orsi, F. Donadio, A. Baccarelli, C. Giavoli, E. Ferrante, A. Lania, A. Spada, Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J. Clin. Endocrinol. Metab. 91(1), 121–128 (2006)CrossRef C.L. Ronchi, V. Varca, P. Beck-Peccoz, E. Orsi, F. Donadio, A. Baccarelli, C. Giavoli, E. Ferrante, A. Lania, A. Spada, Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J. Clin. Endocrinol. Metab. 91(1), 121–128 (2006)CrossRef
20.
Zurück zum Zitat N. Møller, O. Schmitz, J.O. Jøorgensen, J. Astrup, J.F. Bak, S.E. Christensen, K.G. Alberti, J. Weeke, Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J. Clin. Endocrinol. Metab. 74(5), 1012–1019 (1992)PubMed N. Møller, O. Schmitz, J.O. Jøorgensen, J. Astrup, J.F. Bak, S.E. Christensen, K.G. Alberti, J. Weeke, Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J. Clin. Endocrinol. Metab. 74(5), 1012–1019 (1992)PubMed
21.
Zurück zum Zitat K. Mori, Y. Iwasaki, Y. Kawasaki-Ogita, S. Honjo, Y. Hamamoto, H. Tatsuoka, K. Fujimoto, H. Ikeda, Y. Wada, Y. Takahashi, Improvement of insulin resistance following transsphenoidal surgery in patients with acromegaly: correlation with serum IGF-I levels. J. Endocrinol. Invest. 36(10), 853–859 (2013)PubMed K. Mori, Y. Iwasaki, Y. Kawasaki-Ogita, S. Honjo, Y. Hamamoto, H. Tatsuoka, K. Fujimoto, H. Ikeda, Y. Wada, Y. Takahashi, Improvement of insulin resistance following transsphenoidal surgery in patients with acromegaly: correlation with serum IGF-I levels. J. Endocrinol. Invest. 36(10), 853–859 (2013)PubMed
22.
Zurück zum Zitat B. Gallwitz, C. Kazda, P. Kraus, C. Nicolay, G. Schernthaner, Contribution of insulin deficiency and insulin resistance to the development of type 2 diabetes: nature of early stage diabetes. Acta Diabetol. 50(1), 39–45 (2013)CrossRef B. Gallwitz, C. Kazda, P. Kraus, C. Nicolay, G. Schernthaner, Contribution of insulin deficiency and insulin resistance to the development of type 2 diabetes: nature of early stage diabetes. Acta Diabetol. 50(1), 39–45 (2013)CrossRef
23.
Zurück zum Zitat M. Stelmachowskabanaś, G. Zieliński, P. Zdunowski, J. Podgórski, W. Zgliczyński, The impact of transsphenoidal surgery on glucose homeostasis and insulin resistance in acromegaly. Neurol. Neurochir. Pol. 45(4), 328–334 (2011)CrossRef M. Stelmachowskabanaś, G. Zieliński, P. Zdunowski, J. Podgórski, W. Zgliczyński, The impact of transsphenoidal surgery on glucose homeostasis and insulin resistance in acromegaly. Neurol. Neurochir. Pol. 45(4), 328–334 (2011)CrossRef
24.
Zurück zum Zitat A.L. Espinosa-De-Los-Monteros, B. González, G. Vargas, E. Sosa, M. Mercado, Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary 14(3), 231–235 (2011)CrossRef A.L. Espinosa-De-Los-Monteros, B. González, G. Vargas, E. Sosa, M. Mercado, Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary 14(3), 231–235 (2011)CrossRef
25.
Zurück zum Zitat C. Jonas, D. Maiter, O. Alexopoulou, Evolution of glucose tolerance after treatment of acromegaly: a study in 57 patients. Horm. Metab. Res. 48(5), 299–305 (2016)CrossRef C. Jonas, D. Maiter, O. Alexopoulou, Evolution of glucose tolerance after treatment of acromegaly: a study in 57 patients. Horm. Metab. Res. 48(5), 299–305 (2016)CrossRef
26.
Zurück zum Zitat B. Gonzalez, G. Vargas, A.L.E. de Los Monteros, V. Mendoza, M. Mercado, Persistence of diabetes and hypertension after multimodal treatment of acromegaly. J. Clin. Endocrinol. Metab. 103(6), 2369–2375 (2018)CrossRef B. Gonzalez, G. Vargas, A.L.E. de Los Monteros, V. Mendoza, M. Mercado, Persistence of diabetes and hypertension after multimodal treatment of acromegaly. J. Clin. Endocrinol. Metab. 103(6), 2369–2375 (2018)CrossRef
Metadaten
Titel
Surgical outcomes and predictors of glucose metabolism alterations for growth hormone-secreting pituitary adenomas: a hospital-based study of 151 cases
verfasst von
Wenqiang He
Linling Yan
Meng Wang
Qin Li
Min He
Zengyi Ma
Zhao Ye
Qilin Zhang
Yichao Zhang
Nidan Qiao
Yun Lu
Hongying Ye
Bin Lu
Xuefei Shou
Yao Zhao
Yiming Li
Shiqi Li
Zhaoyun Zhang
Ming Shen
Yongfei Wang
Publikationsdatum
20.09.2018
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2019
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1745-7

Weitere Artikel der Ausgabe 1/2019

Endocrine 1/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.